Navigation Links
Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
Date:3/30/2011

itors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this statement related to our product candidates is preliminary and investigative and is not part of the labeling approved by the U.S. FDA or the European Medicines Agency (EMA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or other applicable regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this statement.

CONTACT: Amgen
Carrie Deverell: +41 41 3690 308 (E.U. media)
Christine Regan: +1 (805) 447-5476 (U.S. media)
Arvind Sood: +1 (805)-447-1060 (investors)

(i)  Douillard, JE et al. Randomized, Phase 3 Study (PRIME) of Panitumumab with FOLFOX4 versus FOLFOX4 Alone as First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol 28. 2010.
(ii)  Peeters, M et al. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Sec
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen Donates $1 Million to Help Japanese Disaster Victims
2. Amgen Completes Acquisition of BioVex
3. NBPTS and Amgen Foundation Join to Bolster Science Education
4. Amgen to Present at the Citi 2011 Global Healthcare Conference
5. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing
6. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
7. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
8. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
9. Boehringer Ingelheim to Purchase Amgens Fremont (California) Facility
10. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
11. Amgen to Present at the 29th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor ... nearly 800 doctors have recommended marijuana to the over 112,000 ... 20. But the majority of the other roughly 20,300+ active ... know very little about it – even though a poll ... adults say they have tried it. ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... 2011 Cynosure, Inc. (Nasdaq: CYNO ), ... invasive and non-invasive aesthetic applications, today announced that two ... cellulite reduction have received key international regulatory clearances. ... License authorizing the sale in Canada of the company,s ...
... SANTA CLARA, Calif., March 15, 2011 NewCardio, Inc. (OTC Bulletin ... today that the Company expects to file its Form 10-K for ... management will conduct a conference call to provide a corporate update ... Corporate Update Conference Call When : 1:30 p.m. ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3NewCardio to Conduct Corporate Update Conference Call on March 29, 2011 2
(Date:8/30/2014)... 2014: The first recommendations on the use of ... published today in new ESC Guidelines. The guidelines ... V. Konstantinides (Germany/Greece) and Professor Adam Torbicki (Poland). ... and management of acute pulmonary embolism" are published ... on the ESC Website. , Venous thromboembolism (VTE) ...
(Date:8/29/2014)... The Enchant Him review that was recently published by ... system that promises to teach ladies how to gain control ... who actually is a popular relationship expert and coach. ... advices out there, Carrie worked at this program with Nick ... is a simple to use step by step method. This ...
(Date:8/29/2014)... 29, 2014 The Fibroids Miracle review indicates ... naturally. The program promises fast and powerful results. It actually ... caused by fibroids in only 12 hours. The method promises ... The new system is based on a 3 step method ... its review that the program was in fact created by ...
(Date:8/29/2014)... Colorado (PRWEB) August 29, 2014 According to ... popular hardware detection tool at the moment, as it is ... the best hardware detection tool in the industry. , ... any customer hardware driver. The new program is highly effective ... devices to work perfectly. , Daily Gossip writes in ...
(Date:8/29/2014)... Cosmetic Town has devised a system ... its doctors. Cosmetic Town utilizes a validated referral ... in their field are chosen to present their procedure. ... direct link to potentially hundreds of recommended doctors in ... to communicate through the site’s community features and multimedia ...
Breaking Medicine News(10 mins):Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Enchant Him Review Reveals Unique Relationship Tips for Women 2Health News:Fibroids Miracle Review Exposes Amanda Leto’s 3-Step Holistic System 2Health News:Driver Robot Review Exposes Popular Hardware Detection Tool 2Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2
... resistant to targeted therapy drugs has revealed two previously ... March 23 Science Translational Medicine , investigators from ... how the cellular nature of some tumors actually changes ... can disappear after treatment is discontinued. The findings ...
... , WEDNESDAY, March 23 (HealthDay News) -- ... become resistant to targeted drug therapy. Researchers at ... from 37 patients with non-small cell lung cancer, the ... new genetic changes associated with resistance. They also ...
... study of its kind, urologists and biostatisticians at Henry Ford ... glands is safe over the long term, with a major ... published online this month by the journal European Urology, ... 87 percent of patients whose cancerous prostates were removed by ...
... , TUESDAY, March 22 (HealthDay News) -- Trauma injury patients ... weeknight are no more likely to die than those who ... The findings contrast with previous research that said patients with ... outcomes if they arrive at the hospital at night or ...
... every year there are reports of a young, apparently healthy athlete ... of Wes Leonard, a junior at Fennville High School, who died ... have parents and coaches wondering if enough is being done to ... to develop a better screening program to help prevent sudden cardiac ...
... at Virginia Commonwealth University Massey Cancer Center and VCU ... mechanism in gene regulation that contributes to the development ... (HCC). Currently, there is virtually no effective treatment for ... for therapeutic intervention. In the journal ...
Cached Medicine News:Health News:Mass. General study reveals how lung cancers evolve in response to targeted treatment 2Health News:Mass. General study reveals how lung cancers evolve in response to targeted treatment 3Health News:Lung Cancer Evolves With Treatment, Study Finds 2Health News:Long-term study: Robot-assisted prostate surgery is safe 2Health News:Trauma Patients Seem More Likely to Survive on Weekends 2Health News:Do all student athletes need heart screenings? 2Health News:Do all student athletes need heart screenings? 3Health News:Discovery in liver cancer cells provides new target for drugs 2
A kit will amplify and hybridize 100 samples. Kit components include: Primers, PCR Buffer, dNTPS, Taq Polymerase, Hybridization Solution, Quick-Light™ Buffer, 20 X SSC Concentrate, Lumi-Phos&re...
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
... II Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
Medicine Products: